Log in
Email Address
Password
Forgot your password?
Not Registered?

Featured Tenants

 cfai

The Centre for Advanced Instrumentation at the NETPark Research Institute collaborates with observatories world-wide in the construction, commissioning and exploitation of innovative hi-tech instruments for optical and infrared astronomy. Key research areas are advanced spectroscopy, adaptive optics, applied optics, low light level detectors and precision engineering/metrology.

Click here to learn more about Centre for Advanced Instrumentation

Featured Opportunity
Provision of value innovation specialist support to SME members of NETPark Net

The aim of this contract is to provide individual and tailored support to members of NETPark Net.  This service is expected to be focused on unlocking innovation within the existing operations of the companies and using this discovered potential to increase turnover and profitability, and create jobs.  For further information click here

The deadline is 11th July 2008

Polls



CDEP logo

cddc   eu

Drug could fight many conditions
Bookmark and Share Add This     email Email a Friend    print Printable version

Drug could fight many conditions

2008-05-09
Newsfeed

A new class of drug could be used to treat a wide range of conditions from painful periods to brain haemorrhages.


A new class of drug could be used to treat a wide range of conditions from painful periods to brain haemorrhages.

Vaptans target a hormone system involved in the control of blood flow and water retention in the body.

The drugs can be taken by mouth or injection and work by interfering with the hormone vasopressin.

They act as "antagonists" to block receptors - sensitive sites on cell surfaces - that respond to vasopressin and enable it to function.

Various subclasses of the drug have been developed or are in development. One, known as relcovaptan, has shown positive results in the treatment of painful periods, Raynaud's disease, which causes loss of blood in the fingertips, and tocolysis - premature labour leading to premature birth.

A second vaptans subclass includes the drugs mozavaptan, lixivaptan, satavaptan and tolvaptan. These drugs induce water loss without depleting the body of mineral salts, which often occurs with diuretics.

The drugs are being developed to treat a number of conditions, including kidney failure, kidney damage related to diabetes, cirrhosis and depression.

Preliminary work has also been carried out on the use of vaptans for treating glaucoma, Meniere's disease - a disorder affecting balance - brain haemorrhage and small-cell cancer.

Copyright © The Press Association 2008

<http://www.thelancet.com> (The Lancet)